CT Datasets Now Enable Patient Specific Endovascular Procedure Simulation

July 22, 2014 — Simbionix USA announced the signing of a collaboration agreement with Pie Medical Imaging BV. The company manufactures and distributes the 3mensio software, a clinical application that enables the visualization and analysis of patient computed tomography (CT) scans in both 2-D and 3-D modes. The collaboration will enable the exporting of the 3mensio Vascular model into the Simbionix simulation environment to form a comprehensive planning solution that combines 3DR, data analysis and simulation on the same platform.

The solution will allow physicians and clinical specialists to rehearse a procedure in a complete virtual environment without the need for physical tools. This will take users of the 3mensio software to the next level of preparedness for endovascular procedures, as it will allow added simulation insights. Cases created by the software may also be imported to the Angio Mentor simulator for full procedure practice using fluoroscopy, guidewires, catheters and other equipment that is used in the cath lab.

Simbionix’s PROcedure Rehearsal Studio (PRS) steps up simulation by enabling physicians to rehearse a complete endovascular procedure on a virtual 3-D anatomical model based on a specific patient's CT data. The virtual model can be used for simulating, analyzing and evaluating pre-operative surgical treatment options prior to performing an actual case, which may increase a physician's confidence in the upcoming procedure. Simbionix recently received CE mark for its patient specific simulation.

In addition, Simbionix PRS has recently been granted a patent in China. The company now has patents for this technology in three key countries: the U.S., U.K. and China. These patents represent recognition for Simbionix's comprehensive line of products.

Gary Zamler, Simbionix CEO, said, "Growing interest from the image analysis market, which 3mensio is part of, demonstrates the need for more comprehensive planning solutions. The ability to evaluate surgical treatment options using simulation anytime, anywhere, is a major factor in achieving the goal to increase patient safety and improve procedure outcomes. The collaboration agreement, CE mark and additional patent are all examples of the company's key position as a market leader and innovator in the field of medical simulation."

For more information: www.simbionix.com


Related Content

News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
Feature | Teleradiology | Kyle Hardner

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology ...

Time November 06, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Mammography

Sept. 3, 2025 — According to ARRS’ American Journal of Roentgenology (AJR), a commercial artificial intelligence (AI) ...

Time September 09, 2025
arrow
News | Lung Imaging

Aug. 26, 2025 — Optellum, a global leader in AI for lung health, recently announced the world’s first thorax CT ...

Time August 26, 2025
arrow
News | RSNA 2025

Aug. 13, 2025 — Registration is now open for the RSNA 111th Scientific Assembly and Annual Meeting, the world’s leading ...

Time August 13, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
News | Breast Imaging

QT Imaging Holdings, Inc. has announced the launch of its latest QTviewer, version 2.8. QTviewer stores and displays the ...

Time July 21, 2025
arrow
News | PET-CT

June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research ...

Time June 19, 2025
arrow
News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
Subscribe Now